Ποια είναι η τιμή για Galera Therapeutics, Inc. (GRTX)

Η τιμή για Galera Therapeutics, Inc. (GRTX) είναι $17.15

Ποια είναι η κεφαλαιοποίηση αγοράς για Galera Therapeutics, Inc. (GRTX)

Η κεφαλαιοποίηση αγοράς για Galera Therapeutics, Inc. (GRTX) είναι $6.51M

Galera Therapeutics, Inc. (GRTX) Διαίρεση Μετοχών

Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.

Έτος	Διάσπαση	Πολλαπλασιαστής	Αθροιστικός Πολλαπλασιαστής
2026-07-13	1:200	x0.005	x0.005

Έτος

Διάσπαση

Πολλαπλασιαστής

Αθροιστικός Πολλαπλασιαστής

2026-07-13

1:200

x0.005

Εταιρεία	Αριθμός διασπάσεων μετοχών	Αθροιστικός Πολλαπλασιαστής	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Εταιρεία

Αριθμός διασπάσεων μετοχών

Αθροιστικός Πολλαπλασιαστής

Χώρα